MODERNA (MRNA)
$24.90
0.21 (0.84%)
MRNA Stock Quote Delayed 30 Minutes
7 Deeply Oversold Stocks to Buy Before They Bounce
Stocks often over sell after panicking investors get rid of shares, which eventually leads to the stock bouncing back dramatically.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$25.73
Market Cap
9.69B
PE Ratio
-2.69
EPS
-9.2737
Volume (Avg. Vol.)
16.05M
Day's Range
$23.76 - $25.77
52-Week Range
$23.76 - $170.47
Dividend & Yield
N/A (N/A)
MRNA Stock Predictions, Articles, and MODERNA News
Moderna Stock Will Come Back Stronger After CFO Exit
MRNA stock has been rising for some time now. However, it may see a short-term decline due to the recent departure of its CFO.
Pharma and Rideshare Earnings Roundup
After last week’s Big Tech flub, this week we saw earnings from big names in pharma and “travel comeback” ridesharing plays.
4 Top Stock Trades for Thursday: LYFT, UBER, SBUX, MRNA
Lyft, Uber, Starbucks and Moderna are all moving on earnings and they are our top stock trades for Thursday. Now, let's look at the charts.
Why Is Moderna (MRNA) Stock Up Today?
Moderna (MRNA) stock is on the rise Wednesday following the release of the vaccine company's earnings report for the first quarter of 2022.
Target Deep Value and Give Moderna a Shot
The beatdown in MRNA stock seems overdone as it presents encouraging Covid-19 vaccine results and seeks a crucial regulatory approval.
MRNA Stock Alert: 11 Things to Know as Moderna Seeks FDA Vaccine Approval for Kids
Moderna (MRNA) stock could get a boost after the company revealed an application with the FDA for its Covid-19 vaccine in kids.
Moderna May Have Put Its Best Days Behind It
MRNA stock is up 11% in the last 30 days. However, for many reasons, the stock may face resistance as it tries to move higher.
Moderna’s Lot Recall Is a Blot Despite Its Recent 2nd Covid-19 Booster Approval
MRNA stock could get hurt from a recent recall in Moderna's Covid-19 vaccine, despite other recent good news from an EUA approval.
Concerns About Moderna Stock’s Future Are Overdone
MRNA stock may come back into favor once the market realizes it has overreacted to news of slackening demand for Covid-19 vaccines.
Annual Boosters Might Not Give Moderna the Boost It Needs
Stay Away from MRNA stock, until it either falls to a price where it's arguably a bargain, or if it makes progress bringing non-coronavirus vaccines to market.
MRNA Stock: What’s Going on With Moderna This Week?
Moderna (MRNA) stock is on the move this week after the CDC and the FDA updated their Covid-19 booster shot recommendations.
Investors Seek Second Act with Moderna Stock
Moderna hopes its combination vaccine for COVID and the flu can keep profits high but investors are skeptical. MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline.
